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Impaired cell cycle progression can be paradoxically associated with increased rates of malignancies. Using retroviral
transduction of bone marrow progenitors followed by transplantation into mice, we demonstrate that inhibition of
hematopoietic progenitor cell proliferation impairs competition, promoting the expansion of progenitors that acquire
oncogenic mutations which restore cell cycle progression. Conditions that impair DNA replication dramatically enhance
the proliferative advantage provided by the expression of Bcr-Abl or mutant p53, which provide no apparent
competitive advantage under conditions of healthy replication. Furthermore, for the Bcr-Abl oncogene the competitive
advantage in contexts of impaired DNA replication dramatically increases leukemogenesis. Impaired replication within
hematopoietic progenitor cell pools can select for oncogenic events and thereby promote leukemia, demonstrating the
importance of replicative competence in the prevention of tumorigenesis. The demonstration that replication-
impaired, poorly competitive progenitor cell pools can promote tumorigenesis provides a new rationale for links
between tumorigenesis and common human conditions of impaired DNA replication such as dietary folate deficiency,
chemotherapeutics targeting dNTP synthesis, and polymorphisms in genes important for DNA metabolism.
Citation: Bilousova G, Marusyk A, Porter CC, Cardiff RD, DeGregori J (2005) Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol 3(12):
e401.
Introduction
Despite significant advances in leukemia research, the
factors that promote the selection and expansion of mutated
cells leading to leukemia are not well known. Leukemias
represent abnormal and poorly regulated hematopoiesis, with
leukemia stem cells capable of self-renewal as well as the
generation of multiple cell types [1]. Acquired mutations
contributing to leukemogenesis, including chromosomal
translocations that generate oncogenic fusion genes, may
need to occur in hematopoietic stem cells (HSCs), as these
cells have sufficient lifespan necessary for the acquisition of
additional mutagenic hits. Alternatively, it is possible that
oncogenic events happen in more committed progenitors,
particularly if the mutation confers self-renewal on the cell or
if the cell (such as a B cell progenitor) exhibits a sufficient life
span [1,2].
Chronic myelogenous leukemia (CML) is a clonal myelo-
proliferative disease characterized by excessive proliferation
of progenitor cells with massive accumulation of mature
myeloid lineage cells. Untreated, the chronic phase is
typically followed by an accelerated phase and blast crisis
[3]. The t(9:22) Philadelphia chromosome translocation
product generating p210 Bcr-Abl is the major cause of
CML, and translocations generating either p210 or p190 Bcr-
Abl fusions are present in childhood and adult acute
lymphoblastic leukemias (ALLs). The CML-associated p210
Bcr-Abl gene is found in myeloid, erythroid, and lymphoid
lineage cells in CML patients, suggesting that the trans-
location originally occurred in a pluripotent stem cell [3].
Recent evidence suggests that while the p210 Bcr-Abl fusion is
found in HSC, the leukemia stem cells for both p210- and
p190-associated ALLs possess committed B progenitor
phenotypes [4]. The Bcr-Abl kinase promotes proliferation
and growth factor independence, through the activation of a
number of growth factor signaling pathways [5]. In addition,
Bcr-Abl expression increases genomic instability, in part by
stimulating homologous recombination repair, which can
promote survival after DNA damage, while increasing
recombination and loss of heterozygosity events [6].
A number of contexts associated with decreased cell cycle
progression are, somewhat paradoxically, associated with
high rates of tumors. The loss of the E2F1 and E2F2
transcription factors are generally associated with decreased
proliferation in vitro and in vivo [7,8], consistent with their
roles in promoting the transcription of a variety of genes
required for cell cycle progression. Surprisingly, mice with
mutations in E2f1 and/or E2f2 genes exhibit significantly
increased cancer incidence [9,10]. Until now, the proposed
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tumor suppressive function of E2F1 and E2F2 has been
attributed to decreased E2F-dependent apoptosis, DNA
repair, or gene repression (reviewed in [11,12]). In addition,
dietary folate deficiency, resulting in impaired DNA repli-
cation in cells in vivo, and polymorphisms that reduce dNTP
synthesis are associated with increased colon cancer and
leukemia rates [13,14]. Previous studies have substantiated
that dNTP imbalances caused by folate deficiency or drugs
that inhibit dNTP synthesis can increase DNA damage [14–
16], and enhanced mutation accumulation is thought to
underlie increased tumorigenesis [13,14]. Finally, patients
treated with particular chemotherapeutic regimens, such as
etoposide with methotrexate, are at increased risk of treat-
ment-related acute myeloid leukemia [17]. Etoposide and
methotrexate, which inhibit topoisomerase II and dihydro-
folate reductase respectively, are effective inhibitors of DNA
replication. Chemotherapeutics such as etoposide promote
chromosomal translocations [17], and dNTP imbalances
engendered by methotrexate may further promote mutation
accumulation. Relevant to the studies presented here, genetic,
dietary, and chemotherapeutic inhibitions of the dNTP and
folate metabolic pathways are expected to promote repli-
cative stress and DNA damage, leading to checkpoint
activation and cell cycle inhibition.
While it is logical that conditions that negatively impact on
a cell population could select for mutations conferring
resistance, whether contexts of impaired proliferation con-
tribute to tumorigenesis has not been previously demon-
strated. We show that impaired DNA replication of
hematopoietic progenitors in E2f1/E2f2 mutant mice or mice
treated with hydroxyurea (HU) allows Bcr-Abl-expressing and
p53-mutated progenitors to outcompete nonmutated cells in
the same niche, promoting leukemogenesis.
Results
The Poorly Replicating E2f1/E2f2/ Progenitor
Environment Favors the Competitive Expansion of Bcr-
Abl-Expressing Progenitors
DNA replication in bone marrow (BM) progenitor cell
populations is severely impaired in E2f1/E2f2/ (DKO)
mice, but not in E2f1þ/E2f2þ/mice (phenotypically wild type;
henceforth called E2f1þ2þ), leading to severe hematopoietic
deficiencies [7]. We tested the effects of E2f1 and E2f2
mutation on the expansion and leukemogenicity of cells
expressing the p190 Bcr-Abl fusion oncogene, which is
preferentially associated with ALL in humans [5]. For most
experiments, we limited transduction with mouse stem cell
viruses (MSCVs) encoding Bcr-Abl and/or green fluorescent
protein (GFP) to only a small percentage of progenitors to
more accurately reflect the rare occurrence of oncogenic
initiating events in a background of unmutated cells, allowing
for competition between Bcr-Abl-positive and -negative
progenitor cells. The transduced cells were then transplanted
into wild-type irradiated recipient mice, and competitive
reconstitution was analyzed (see Figure 1 for the experimen-
tal design).
At low transduction efficiencies (less than 5% of trans-
planted cells expressing Bcr-Abl), we found that Bcr-Abl
expression clearly provides a substantial advantage for DKO,
but not E2F1þ2þ progenitors, as reflected by contributions to
peripheral blood cells at 3 wk post-BM transplantation (BMT)
(Figure 2A and 2B). The recipients of Bcr-Abl-transduced
DKO cells had dramatically increased percentages of B cells
and myeloid cells expressing Bcr-Abl. Increased contribu-
tions of Bcr-Abl-expressing cells in the DKO relative to
E2F1þ2þ background were also observed at high infection
efficiency, although a modest (but for many recipients,
transient) advantage of Bcr-Abl expression was evident
among E2F1þ2þ cells in terms of contributions to mature
blood cells (Figure S1). As a control, we transduced BM
progenitors with vector expressing GFP only, and in
numerous experiments we found that E2f1/E2f2 loss did not
noticeably affect the ability to transduce stem and progenitor
populations, as similar short-term and long-term reconstitu-
tion of all lineages as determined by GFP expression was
observed in recipients of vector-transduced E2f1þ2þ and DKO
BM progenitors (Figures 2A, 2C, and unpublished data).
In order to directly determine contributions to hemato-
poietic progenitor populations, we analyzed BM from the
same set of mice for the expression of GFP (vector or Bcr-Abl)
in particular progenitor pools. The lineage negative (Lin)
population in the BM expresses low levels of lineage-specific
markers, and is thus enriched for progenitor cells. The Lin
Flk2 Sca1þ population is enriched for HSC but will also
include short-term progenitors [18]. Of note, while Sca1 is
expressed on only about 25% of HSC in BALB/c mice, the
Lin Sca1þ population is substantially enriched for long-term
HSC activity in these mice [19]. We observed a dramatic
selective advantage for Bcr-Abl expression in the Lin Flk2
Sca1þ population in the DKO, but not the E2f1þ2þ, back-
ground (Figure 2C, upper right quadrants), correlating with
contributions to peripheral blood cells. Of note, a transient
advantage within more committed progenitors (such as Lin
Sca1 cells; Figure 2C, lower right quadrants) is often evident
for Bcr-Abl expression in E2f1þ2þ cells. As we find that c-Kit is
down-regulated on Lin Sca1þ cells post-BMT (unpublished
data), we have been unable to further examine Bcr-Abl
expression among highly defined HSC. In summary, Bcr-Abl
expression provides a dramatic competitive advantage to
progenitor cells in the replication-impaired DKO back-
ground, but not in the replication-competent E2f1þ2þ back-
ground.
Figure 1. Experimental Design
DOI: 10.1371/journal.pbio.0030401.g001
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The Expression of Bcr-Abl Restores S Phase Progression in
DKO Progenitor Cells
The competitive expansion of Bcr-Abl-expressing cells
relative to untransduced cells in the DKO background could
be the result of overcoming cell cycle defects observed in
DKO progenitors. To test this possibility, we assayed the
effect of Bcr-Abl expression on S-phase progression rates in
DKO progenitor cells using a bromodeoxyuridine (BrdU)
pulse-chase method [20]. Two weeks post-BMT, at which
point no signs of leukemia development were evident, mice
were injected with BrdU and then sacrificed after 2 h. BrdU
injection essentially provides a short pulse of the label, since
BrdU half-life in vivo is very short [21]. Following flow
cytometric isolation of GFPþ Lin or GFP Lin progenitors
from the spleen, the average DNA content of BrdU-positive
cells was assayed by propidium iodide (PI) intensity profiling.
The rates of S phase progression were determined as the shift
of the average PI intensity from the middle of S phase toward
the G2 peak using formulas described by Begg et al. [20].
Although the calculated progression rates do not provide
accurate absolute values for S phase length, since the
presumption that the average PI intensity lies in the middle
of S phase is not true for DKO cells (which accumulate in
early S phase [7]), this method can still accurately analyze the
changes of the rates caused by Bcr-Abl expression. Signifi-
cantly, while S phase progression is substantially slowed in
Figure 2. The Expression of Bcr-Abl Provides a Competitive Advantage to DKO Progenitors
Purified c-Kitþ cells from either E2f1þ2þ or DKO donor mice (pooled sets of littermates) were transduced with MSCV-expressing p190 Bcr-Abl and GFP or
GFP only (vector), and transplanted into lethally irradiated BALB/c recipients. The same pool of Bcr-Abl transduced DKO progenitors was either mixed
with untransduced E2f1þ2þ competitor progenitors (‘‘DKOþE2F1þ2þ competitors’’) or with untransduced DKO progenitors (‘‘DKO’’). Bcr-Abl-transduced
E2f1þ2þ progenitors similarly were mixed with untransduced E2f1þ2þ progenitors (‘‘E2F1þ2þ’’). Specifically, each recipient received 2.5 3 105
untransduced whole BM cells combined with 1.23 106 MSCV-transduced c-Kitþ cells. Initial infection efficiencies measured for the whole c-Kit-enriched
population were 5.1% and 3.75% among E2f1þ2þ, and 4.73% and 3.4% among DKO progenitors for Bcr-Abl and vector, respectively. Tail blood isolated
at 3 wk post-BMT was analyzed for the expression of GFP and B220 (upper bar graph; B-cell lineage) or GR-1 (lower bar graph; myeloid lineage) by flow
cytometry.
(A) Each bar represents data from five mice with standard error (SE) indicated, and statistical significance determined using Student’s unpaired t-test (for
all figures in this paper).
(B) Representative flow cytometric profiles of peripheral B cells are shown, with the percentages of peripheral blood cells expressing both GFP and B220
indicated.
(C) BM cells were analyzed by flow cytometry for the expression of Lin antigens, Sca1, Flk2 and GFP. Lin antigens included GR-1, B220, Ter119, CD3, and
CD4. Cells analyzed in the profiles shown were gated as Lin Flk2. The upper right quadrant represents progenitor-enriched Lin Flk2 Sca1þ cells
expressing either Bcr-Abl or vector, and the percentages of Lin Flk2 cells that express Sca1 and/or GFP are indicated. In multiple experiments,
recipients of Bcr-Abl transduced E2f1þ2þ cells exhibited reduced percentages of GFP Lin Flk2 Sca1þ cells (the upper left quadrant) relative to vector
controls, a phenomenon that we do not currently understand.
DOI: 10.1371/journal.pbio.0030401.g002
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DKO progenitor cells, as previously reported [7], the
expression of Bcr-Abl in these cells essentially restored S
phase progression to control progression rates (Figure 3). In
contrast, the expression of Bcr-Abl had no noticeable effects
on S phase progression in wild-type progenitors. In addition,
we previously showed that a fraction of DKO BM progenitors
appear arrested in S phase, exhibiting S phase DNA content
but no detectable BrdU incorporation [7]. As shown in Figure
3A, Bcr-Abl expression in DKO progenitors prevents the
accumulation of this S phase-arrested population.
Thus, the competitive advantage provided by Bcr-Abl
expression to DKO progenitors appears to derive from
restored cell cycle progression. Furthermore, as we find that
the expression of Bcl2 does not provide an advantage to DKO
progenitors relative to wild-type progenitors (Figure S2), the
ability of Bcr-Abl to block apoptosis does not appear to
underlie the selective advantage conferred by Bcr-Abl
expression in the DKO background, although decreased
apoptosis could be a contributing factor.
The DKO Background Promotes Bcr-Abl-Mediated
Leukemogenesis
As leukemogenesis appears to require initiating mutations
in stem or progenitor cell populations, we addressed whether
the greater competitive advantage provided to Bcr-Abl-
expressing DKO progenitors translates to increased tumor
incidence in transplanted mice. Strikingly, all recipients of
Bcr-Abl-transduced DKO progenitors developed rapid pre-B
ALL-like disease using both low and high initial transduction
efficiencies (Figures 4A and 4B), preceded by rapid increases
of peripheral GFPþ B220þ cells (Figures 2A and S1). In
contrast, only about half of the recipients of E2f1þ2þ cells
transduced at high efficiency, and none of the recipients at
low transduction efficiency, developed leukemia (also pre-B
ALL; Figure 4). For leukemias arising in both genetic
backgrounds, leukemic infiltrates were evident in spleen,
liver, and lung, and peripheral blood GFPþ cells expressed low
B220, exhibiting a large, immature morphology with pale-
staining nuclei (Figure 4C and unpublished data). Leukemia
cells in the spleen and BM were mostly negative for the Lin
markers GR-1, Ter119, CD4, and CD3 (unpublished data),
expressing from undetectable to low B220 levels depending
on the leukemias (Figure 4C; examples shown express little to
no B220). Interestingly, we consistently observed a greater
fraction of Sca1þCD34þ cells in DKO relative to E2f1þ2þ
leukemias (Figure 4C), consistent with the early advantage
provided by Bcr-Abl expression in DKO progenitor-enriched
populations (Figure 2C).
E2f1þ2þ Competitors Effectively Suppress Leukemia
Development by Bcr-Abl-Expressing DKO Progenitors
While leukemogenesis correlates with the ability of Bcr-
Abl-expressing cells to competitively expand within progen-
itor pools, based on increased leukemia rates alone we cannot
distinguish whether or not cell autonomous effects of E2f1/
E2f2 loss, such as accelerated mutagenesis or decreased
apoptosis, are the major factors underlying increased
leukemia rates. To directly address this issue, we included
E2f1þ2þ untransduced competitor cells with Bcr-Abl-trans-
duced DKO progenitors; amazingly, these competitors were
able to almost completely eliminate leukemogenesis (Figures
4A and 4B). E2f1þ2þ competitors also substantially reversed
the selective advantage conferred by Bcr-Abl expression in
the DKO background as reflected in peripheral blood cells
(Figures 2A, 2B, and S1) and within stem cell-enriched
populations (Figure 2C). Similarly, transplantation of Bcr-
Abl-transduced DKO progenitors into sublethally irradiated
recipients resulted in the rebound of host (wild-type)
hematopoiesis and complete prevention of leukemias (un-
published data). Thus, enhanced leukemogenesis is not
primarily due to cell autonomous effects of E2f1 and E2f2
loss, but most likely results from the poor ability of DKO
Figure 3. Bcr-Abl Restores S Phase Progression in DKO Progenitors
Wild-type or DKO donor mouse c-Kitþ cells were transduced with MSCV-
Bcr-Abl or vector and transplanted as in Figure 2 but at higher efficiency.
(A) Recipients were injected 3 wk post-transplant with BrdU and spleen B
cell and myeloid progenitors (combined) isolated by flow sorting,
separating GFPþ from GFP. Immunofluorescence for BrdU together with
PI staining for DNA content are shown for GFP cells (internal control)
and GFPþ cells from E2f1þ2þ or DKO recipients of Bcr-Abl-transduced
stem cells. The percentages of cells with S phase DNA content but
without significant BrdU incorporation (in the small square) are
indicated.
(B) The histograms shown in the insets in (A) plot the DNA content of
cells gated as BrdUþ, which are used to calculate the average lengths of S
phase (from two experiments, 6 SE).
DOI: 10.1371/journal.pbio.0030401.g003
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progenitor cells to compete with Bcr-Abl-expressing DKO
progenitors.
Importantly, these results suggest that the failure of many
recipients of Bcr-Abl-transduced E2f1þ2þ (particularly at low
transduction efficiency) to develop leukemia was not due to
our inability to introduce Bcr-Abl into the appropriate
progenitor cells, but to the inability of Bcr-Ablþ progenitors
to be maintained in the face of replication competent
competitors. Finally, while it remains formally possible that
DKO stem/progenitor cells home poorly to BM niches and
that Bcr-Abl restores homing to DKO progenitors, the fact
that a low percentage of cotransplanted E2f1þ2þ BM can
reverse the selective expansion of Bcr-Ablþ DKO progenitors
and leukemogenesis (Figures 4 and S1) strongly argues against
a role for differential homing in genotype-dependent
leukemia rates.
In summary, a DKO progenitor pool promotes Bcr-Abl-
dependent leukemogenesis due to the inability of untrans-
duced DKO progenitors to provide effective competition.
The ability of Bcr-Abl to restore S phase progression to
replication impaired DKO progenitors most likely underlies
the competitive advantage provided by Bcr-Abl specifically
within the DKO background.
HU Promotes the Competitive Expansion of Bcr-Abl-
Expressing Blood Progenitors Ex Vivo
In order to further explore the generality of the selection
for Bcr-Abl-expressing cells under conditions of impaired
DNA replication as well as to examine Bcr-Abl-mediated
leukemogenesis in a more clinically relevant context, we
asked how the suppression of proliferation within hema-
topoietic progenitor pools during treatment of mice with
HU, an inhibitor of ribonucleotide reductase, affects Bcr-Abl-
dependent competition within wild-type BM. HU has been
used for over 40 y as a cytostatic drug [22]. HU-induced dNTP
depletion results in replication stalling and the activation of
checkpoint pathways [23]. We initially asked whether HU
treatment creates a poorly competitive environment that
favors the expansion of Bcr-Abl-expressing blood progenitors
ex vivo. As shown in Figure 5A, HU differentially affected
Bcr-Abl- and vector-expressing progenitors, allowing Bcr-Ablþ
Figure 4. E2f1/E2f2 Loss Promotes Bcr-Abl-Mediated Leukemias
(A and B) E2f1þ2þ or DKO mouse c-Kitþ cells were transduced with MSCV-Bcr-Abl and transplanted as in Figure 2, except that in (B) a higher initial
transduction efficiency was obtained (23.2% for E2f1þ2þ and 24.1% for DKO). Initial transduction efficiencies for (A) were the same as in Figure 2.
Untransduced competitors were included as described in Figure 2, except that for the experiments shown in (B), competitors were c-Kitþ-purified BM
cells cultured in parallel to the transduced cultures but not infected, and each recipient mouse received 1.53 105 untransduced c-Kitþ competitors
combined with 1.43106 Bcr-Abl-transduced progenitors. Kaplan-Meier curves are shown for both experiments. Mice were sacrificed when moribund, all
with splenomegaly and lymphadenopathy. No mice transplanted with vector-expressing cells developed leukemia (unpublished data). The Kaplan-
Meier curves for Bcr-Abl/DKO are statistically different from the Bcr-Abl/ E2f1þ2þ (p , 0.001 for [A] and p , 0.0001 for [B]) and Bcr-Abl/DKOþ E2f1þ2þ
competitors (p , 0.001 for [A], p , 0.02 for [B]) curves.
(C) Peripheral blood, spleen, and BM from morbid leukemic Bcr-Abl BMT mice or from healthy vector BMT mice (from [B]) were analyzed for the
expression of the indicated antigens and GFP by flow cytometry. Peripheral blood was analyzed 21 d post-BMT. The recipient of Bcr-Abl/DKO cells was
sacrificed at 23 d and other recipients sacrificed at 29 d post-BMT. The mean fluorescence intensities (mfi) for peripheral B220þ cells are indicated.
DOI: 10.1371/journal.pbio.0030401.g004
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cells to competitively expand. In fact, while the expansion of
vector-expressing progenitors was almost completely in-
hibited by all concentrations of HU used, Bcr-Abl-expressing
progenitors continued expanding at doses ranging from 5 to
25 lM (Figure 5A, lower panels). Higher doses of 50 and 100
lM HU did effectively inhibit the expansion of Bcr-Ablþ
progenitors, indicating that the advantage provided by Bcr-
Abl expression during HU treatment is relative but not
absolute. While Bcr-Abl expression alone provided a modest
advantage to wild-type progenitors in culture, 5 to 25 lM HU
treatment conferred an even greater advantage to Bcr-Abl-
expressing cells (Figure 5A, upper panel). Furthermore, as
determined by GFP expression levels, HU selects for cells
expressing higher levels of Bcr-Abl (Figure 5B). Notably,
increased Bcr-Abl expression is commonly observed in
patients during CML progression from chronic phase to
blast crisis [24].
HU Treatment Provides a Competitive Advantage to Bcr-
Abl-Expressing Progenitors In Vivo
Mice were transplanted with MSCV-p190 Bcr-Abl-trans-
duced BALB/c BM progenitor cells, and half of the recipients
were switched to water containing HU (20 mg/kg/d; similar to
doses used clinically for cytoreduction [22]) at 2 wk post-
BMT. Strikingly, by 5 and 8 d after switching recipient mice
to HU, a substantial competitive advantage for Bcr-Ablþ cells
within the progenitor-enriched Lin Sca1þ population was
evident, while a similar selection for Bcr-Abl expression was
not observed without HU treatment (Figure 6A). Note that
about two-thirds of the progenitor-enriched Lin Sca1þ cells
expressed Bcr-Abl in HU-treated mice, while very few Bcr-Ablþ
Lin Sca1þ cells were detected in untreated mice, despite the
fact that these mice were transplanted with the same pool of
transduced BM progenitors. The rapid competitive advantage
provided by Bcr-Abl specifically following HU treatment in
vivo, together with the almost immediate selection for Bcr-
Abl expression by HU ex vivo, argues that HU-induced
mutagenesis does not account for the effects of HU on the
competitive expansion of Bcr-Ablþ progenitors.
To understand why Bcr-Abl provides such an advantage
specifically following HU treatment, we analyzed cell cycle
progression in Bcr-Abl-expressing progenitors in vivo using
the same method used for Figure 3. While HU decreased the
percentage of cells undergoing DNA synthesis and increased
the length of S phase, Bcr-Abl expression resulted in more
normal S phase progression in leukocytic progenitors in HU-
treated recipients (Figure 6B). This result provides a
mechanistic insight into why HU treatment improves the
competitive expansion of Bcr-Abl-expressing progenitors in
vivo and ex vivo: While HU impedes the proliferation of
competing progenitors, Bcr-Abl overcomes this block. In
contrast, Bcr-Abl expression does not appear to affect DNA
replication in untreated progenitors, and thus Bcr-Abl
expression does not provide an apparent competitive edge
without HU.
Figure 5. HU Promotes the Competitive Expansion of Bcr-Ablþ Blood Progenitors Ex Vivo
(A) BALB/c c-Kitþ BM cells were transduced with MSCV-Bcr-Abl or vector and cultured in stem cell medium with HU (0, 5, 10, 25, 50, or 100 lM) added
starting at day 3. Flow cytometric analysis of GFP expression and total cell counting in cultures were performed every 3–4 d. The changes in GFP
percentages in vector and Bcr-Abl cultures (upper graphs) and the cumulative expansion (loge scale) of Bcr-Abl
þ and vector cells (lower graphs) during
HU treatment were plotted.
(B) The percentages of cells expressing Bcr-Abl (day 13) as well as the mean fluorescence intensities (mfi) for the GFPþ population, which has been
shown to reflect Bcr-Abl protein expression [35], are indicated. Most Bcr-Ablþ cells were c-KitþCD34þ, with or without HU treatment. HU treatment did
not affect the intensity of GFP in vector cells (unpublished data).
DOI: 10.1371/journal.pbio.0030401.g005
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HU Treatment Accelerates and Increases the Penetrance
of Bcr-Abl-Mediated Leukemias
We addressed whether HU treatment of mice with Bcr-Ablþ
progenitors promotes leukemogenesis in vivo. For each
experiment, aliquots from a single pool of MSCV-Bcr-Abl (or
vector)-transduced BALB/c BM stem cells were transplanted
into multiple syngeneic recipients. For all recipients, ;3% of
peripheral B cells were GFPþ at 2 wk post-BMT, at which
point half of the mice were switched to water containing HU.
By treating with HU starting 2 wk post-BMT, potential effects
of HU on retroviral infection efficiency or homing to BM
niches are avoided. Strikingly, all of the HU-treated mice
developed a pre-B ALL-like disease within 2 mo (Figure 7A)
preceded by increases in the percentages of Bcr-Ablþ cells in
the B220þ subset (unpublished data). In contrast, mock-
treated mice that received Bcr-Abl-transduced stem cells
developed leukemia with much lower penetrance (3 of 8)
and longer latency periods. HU treatment also enhanced
leukemogenesis induced by p210 Bcr-Abl, although interest-
ingly, these mice all succumbed to CML-like disease (Figure
7B). Thus, in our model system, p190 Bcr-Abl causes B-ALL
and p210 causes CML, thus closely modeling the human
diseases caused by the respective translocation products.
Given that HU treatment promotes the expansion of Bcr-Ablþ
progenitors within 5 d (Figure 6A), it is improbable that HU-
promoted mutagenesis alone accounts for more rapid
disease, although increased mutation accumulation may be
a contributing factor. Furthermore, as HU similarly promotes
leukemogenesis in analogous experiments using donor BM
from Rag2/ mice, in which case mature T and B cells were
nearly undetectable in recipients (Figure S3), HU-mediated
Figure 6. HU Selects for Bcr-Abl Expression Within Hematopoietic Progenitor Pools In Vivo
BALB/c c-Kitþ BM cells were transduced with the indicated retroviruses, and transplanted into sublethally irradiated BALB/c recipients. At 2 wk post-BMT,
half of each group was switched to water containing HU.
(A) BM cells were analyzed for the expression of Lin antigens, Sca1, and GFP as described in Figure 2C on days 5 and 8 of HU treatment. Cells analyzed in
the profiles shown were gated as Lin. The percentages of the progenitor enriched Lin Sca1þ population that expressed vector or Bcr-Abl are indicated
in the upper right corners (underlined).
(B) Four days after switching to HU water (or not), mice were injected with BrdU, and spleen GFPþ and GFP Lin progenitors isolated by flow sorting as
in Figure 3. BrdU incorporation is detected in GFP cells (internal control) and GFPþ cells, and the calculated average lengths of S phase from two
experiments is shown in the graph.
DOI: 10.1371/journal.pbio.0030401.g006
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increases in Bcr-Abl-dependent leukemogenesis does not
appear to result from immunosuppression.
Leukemic p190 Bcr-Abl recipient mice exhibited massive
increases in pre-B-like large B220þ CD43þ cells, high
leukocyte blast counts in peripheral blood, and splenomegaly
(Figures 7C and S4). Pathological characterization of spleens
and other tissues determined that the lymphoproliferative
diseases arising in all HU and the three non-HU-treated mice
were large cell leukemias, with frequent involvement of liver,
lung, and spleen (unpublished data). Spleens contained a
mixture of leukemic cells, with most exhibiting lymphoid
characteristics and a subset exhibiting a myeloid phenotype
(unpublished data). For most HU (relative to non-HU)-
treated mice, the predominant GFPþ (i.e., Bcr-Ablþ) popula-
tion in the BM and spleen contained a more substantial
subpopulation of cells expressing the progenitor markers c-
Kit and CD34 (Figure 7D). We transplanted spleen or BM cells
(103–105) from morbid leukemic HU- and non-HU-treated
Bcr-Abl BMT recipients into BALB/c recipients, and most
recipients for both groups developed leukemia, underscoring
the malignant nature of the leukemias (Figure S5). Thus, by
providing a competitive advantage to Bcr-Ablþ progenitor
cells (as shown ex vivo and in vivo), HU treatment promotes
Bcr-Abl-mediated ALL and CML.
The Inhibition of p53 Provides a Competitive Advantage
to DKO BM Progenitors
While our experiments provide strong evidence that
backgrounds of impaired DNA replication enhance the
competitive expansion of Bcr-Abl-expressing cells, we wanted
to test if this phenomenon can be applicable to other
oncogenic events. The p53 tumor suppressor gene is mutated
in over half of human tumors, and mutation of p53 has been
shown to disrupt checkpoints that prevent cell cycle
Figure 7. HU Treatment Enhances Bcr-Abl-Mediated Leukemogenesis
Bcr-Abl BMT recipients were generated and treated with HU as described in Figure 6.
(A–B) Kaplan-Meier curves for vector (A), p190 Bcr-Abl (A), or p210 Bcr-Abl (B) transduced stem cell-transplanted mice with or without HU treatment are
shown. The curves for p190 and p210 Bcr-Abl with HU are statistically different from the respective Bcr-Abl-untreated curves (p , 0.001 and p , 0.05,
respectively). For (A) and (B), the average percent GFPþ in peripheral blood cells was 3%, and mice with similar percentages were segregated into the
HU-treated and untreated groups. Mice were sacrificed when moribund, all with splenomegaly and massive increases in B220þGFPþ (for p190) or GR-
1þGFPþ (for p210) cells in the spleen and peripheral blood.
(C) Peripheral blood from morbid p190 Bcr-Abl-BMT mice (with or without HU, as in Figure 6) or from a healthy vector BMT mouse was analyzed for B220
and GR-1 expression by flow cytometry.
(D) BM cells from morbid p190 BMT mice were analyzed for the expression of c-Kit, CD34, CD43, B220, with side scatter and forward scatter (reflects cell
size) as indicated. The dashed oval indicates the typical position of normal BM pre/pro-B-cells. All leukemic BM cells in untreated Bcr-Abl recipients
expressed B220 and CD43 as shown in the upper panels. Leukemic BM cells from HU treated mice generally expressed less B220 (despite B220
expression in peripheral cells; see (A) and displayed more c-Kitþ and many more CD34þ cells. Percentages shown are averages (6 SD) for three mice for
each group. Two Bcr-Ablþmice treated with HU that developed leukemia late (7 and 10 wk post-BMT) displayed an immunophenotype more similar to
the Bcr-Abl-untreated mice.
DOI: 10.1371/journal.pbio.0030401.g007
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progression in the face of various cellular stresses [25].
Mutation of p53 in human cancers frequently results in the
expression of a dominant negative mutant p53 protein
(DNp53) that forms inactive multimers with wild-type p53.
Given the known ability of DNp53 to alleviate checkpoint-
dependent cell cycle arrests, we asked whether the expression
of DNp53 (175H) could provide a competitive advantage for
E2f1/E2f2 mutant progenitor expansion. In addition, we
engineered a retrovirus to express the oligomerization
domain of p53 (DDp53), which also inhibits p53 activity
[26]. Strikingly, MSCV-mediated expression of DNp53 or
DDp53 in hematopoietic progenitors from DKO, but not
wild-type, mice resulted in a dramatic selective advantage for
these cells after only 2 wk post-BMT (Figure 8A). Again, the
percentages of peripheral blood cells expressing vector were
very similar for wild-type and DKO cells. Thus, the inhibition
of p53 provides a competitive advantage during hematopoi-
esis in DKO, but not wild-type, BM.
We used genetic disruption of p53 [27] as an alternative to
retroviral DNp53 expression. We bred the p53 mutation into
the E2f1/E2f2 mutant and BALB/c backgrounds together with
a ubiquitously expressed GFP transgene [28]. In competitive
BMT experiments using wild-type BM in competition with
p53/GFPþ BM (93:7 ratio), p53/GFPþ BM contributions to
hematopoiesis were similar to its percentage within the
original BM transplanted (Figure 8B), indicating that p53
mutation does not provide an immediate competitive
advantage during hematopoiesis. In contrast, DKO/p53/
GFPþ BM progenitors exhibited significant competitive
expansion relative to DKO progenitors, and this competitive
expansion was completely abrogated by the inclusion of
E2f1þ2þ competitors (Figure 8B; compare second and third
columns). Thus, as in the Bcr-Abl experiments shown in
Figure 2, the increased expansion of DKO/p53/ cells in a
DKO background relative to p53/ cells in a wild-type
background is not due to cell autonomous contributions of
E2f1/E2f2 loss, but instead to the poor competition provided
by DKO hematopoiesis.
Discussion
Given that deregulated cell cycling is considered a hallmark
of tumorigenesis [29], it is natural to assume that contexts
that promote proliferation would promote cancer. Studies in
search of connections between genetic polymorphisms, diet-
ary factors, and environmental exposures that predispose to
cancer are often predicated on the assumption that increased
cancer rates in part result from the enhancement of
proliferation by these conditions [30–33]. We show that the
opposite can be true. Our data indicate that the reduced
ability of progenitor cell pools to proliferate actually
promotes tumorigenesis, in that cells acquiring mutations
that improve proliferation outcompete poorly replicating
competitors. In contrast, a replication-competent pool is
inherently tumor-suppressive, and otherwise oncogenic mu-
tations may not be favored.
We have shown that within a wild-type, healthy progenitor
cell pool, Bcr-Abl expression or p53 inhibition does not
provide an apparent selective advantage. In contrast, in
contexts of impaired DNA replication of blood progenitors,
expression of Bcr-Abl or inhibition of p53 provides an
immediate advantage within progenitor pools. The expres-
sion of Bcr-Abl bypasses the S phase blocks imposed by E2f
mutation or HU treatment, consistent with the known ability
of Bcr-Abl to abrogate cell cycle checkpoints. As Bcr-Abl
expression provides an immediate competitive advantage
following HU treatment ex vivo, the advantage appears to
result from the better proliferation of Bcr-Ablþ cells relative to
untransduced peers, not effects of HU on mutagenesis or the
immune system, or other potential complications found in
vivo. Most importantly, replication-impaired contexts (both
genetic and chemotherapeutic) can substantially promote
Bcr-Abl-dependent leukemias. That Bcr-Abl-expressing cells
with restored S phase progression outcompete untransduced
cells with highly impaired replication provides a logical
explanation for the promotion of leukemogenesis by HU
treatment and E2f1/E2f2 loss. Indeed, the promotion of Bcr-
Abl-dependent leukemias by E2F mutation is not due to cell
autonomous contributions of E2f1/E2f2 loss, as E2f1þ2þ
competitors virtually eliminate leukemias resulting from
Bcr-Abl expression in DKO progenitors. Thus, healthy
competitors are potently tumor-suppressive.
The presented results support a model whereby the
Figure 8. The Inhibition of p53 Provides a Competitive Advantage for
DKO, but Not Wild-Type, BM Progenitors
(A) Wild-type or DKO BM cells were transduced with MSCV-DNp53,
MSCV-DDp53, or vector, and transplanted into lethally irradiated BALB/c
recipients. At 2 wk post-BMT, the percentage of GFPþ cells among
peripheral blood GR-1þ cells was determined by flow cytometry. The
contribution of GFPþ cells after 2 wk relative to the initial infection
efficiency is shown. Initial infection efficiencies for each virus were similar
for the two BM genotypes.
(B) Genetic disruption of p53 provides a proliferative advantage in the
DKO but not wild-type background. The indicated mixtures of freshly
harvested BM were used to reconstitute the hematopoietic system of
lethally irradiated recipient BALB/c mice. At 6 wk post-BMT, the
percentage of GFPþ nucleated cells in peripheral blood was determined
by flow cytometry and fold expansion was determined relative to the
initial mixture.
DOI: 10.1371/journal.pbio.0030401.g008
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reduced proliferation of blood progenitors provides a
powerful selection for oncogenic mutations that improve
cell cycle progression. In essence, impeded proliferation of
progenitor cells provides for poor competition, promoting
the expansion of progenitors that acquire oncogenic muta-
tions which relieve cell cycle blocks (Figure 9). In addition, the
ability of some oncogenic mutations to impede apoptosis
resulting from checkpoint activation might further contrib-
ute to a net competitive advantage. It has been previously
proposed that carcinogen-mediated inhibition of cell survival
or proliferation can select for oncogenically mutated cells
resistant to these conditions ([34] and references therein).
Analogously, we show that conditions that impair DNA
replication in the entire population of progenitor cells select
for oncogenic mutations that initiate tumorigenesis. In
contrast, oncogenic mutations prove less advantageous or
even disadvantageous in a normal hematopoietic system, as
cell cycle progression in the progenitor pool is already
efficient, and checkpoints should not be activated. Finally,
contexts that involve nucleotide deprivation and DNA
damage, and thus impeded DNA replication, may enhance
mutation accumulation, and mutator phenotypes should
synergize with poor competition to promote tumorigenesis.
Thus, these conditions provide not only an increased chance
for the acquisition of initiating mutations, but also a poorly
competitive environment that favors the expansion of these
oncogenically mutated cells. In this regard, it is unlikely that
all conditions that globally impair cell cycle progression in a
stem cell pool will promote tumorigenesis, particularly if
these impaired contexts cannot be easily overcome by
oncogenic mutation or do not sufficiently promote mutation
accumulation. Moreover, while impaired replication can
clearly select for the expression of oncogenes such as Bcr-
Abl and DNp53, other oncogenic events (like Bcl2 over-
expression) may not be selected for and may even be selected
against.
The low leukemia incidence that we observed in the
replication competent-backgrounds may seem at odds with
previous reports of efficient induction of CML-like disease in
recipients of MSCV-Bcr-Abl-transduced BM cells using high-
efficiency infections [35–37]. So why would MSCV-Bcr-Abl
transduction result in rapid and penetrant onset of leukemia
with high- but not low-efficiency infection, given that normal
hematopoietic stem and progenitor cells, and thus healthy
competitors, are still present in both cases? One possibility is
that the resulting high percentage of cells expressing Bcr-Abl
could result in substantial autocrine stimulation, which may
not reflect the normal context of a rare Bcr-Abl fusion event.
Indeed, expression of Bcr-Abl in cytokine-dependent cell
lines leads to growth factor-independent proliferation
associated with autocrine production of interleukin-3 (IL-3)
and granulocyte/monocyte-colony stimulating factor [38–40],
and increased levels of IL-3 are detected in serum in murine
models of CML [36,37]. Importantly, retroviral expression of
IL-3 by BM cells is sufficient to induce a myeloproliferative
syndrome in mice [41–43]. Furthermore, Bcr-Ablþ cells secrete
inhibitors of normal hematopoiesis that induce apoptosis in
normal but not Bcr-Ablþ cells [44]. Autocrine stimulation by
Bcr-Abl-expressing cells and inhibition of normal hemato-
poiesis should have a far greater impact when a large
percentage of cells express Bcr-Abl, as compared to the
physiological context of an initiating mutation leading to the
expression of the oncogene in a single clone. Nonetheless,
these activities could still be very relevant to the progression
of Bcr-Ablþ leukemias, in that once a Bcr-Ablþ clone has
reached some critical mass, the clone may promote its own
competitive expansion even in the face of normal hemato-
poietic competitors. Finally, high-efficiency transduction of
progenitors should increase the chance of secondary muta-
tions that promote Bcr-Abl-dependent leukemogenesis,
including gene alterations mediated by retroviral integra-
tions.
An important point is that most of the recipients of control
(E2f1þ2þ or wild-type without HU) progenitors transduced
with Bcr-Abl did not develop leukemia. Indeed, for surviving
mice, GFP expression in peripheral blood became undetect-
able (unpublished data), indicating that Bcr-Abl expression is
disfavored in stem cell pools in the long-term. The facts that
(1) the same pool of Bcr-Abl-transduced BM progenitors was
transferred into recipients that subsequently were mock- or
HU-treated, and (2) all HU-treated Bcr-Abl recipients rapidly
developed leukemia, indicate that most of the nonleukemic
mice in the control group did receive Bcr-Ablþ progenitors
capable of causing leukemia, but that these cells were not
maintained. In contrast, HU treatment clearly promoted the
expansion of Bcr-Ablþ cells, stimulating leukemogenesis.
Analogously, Bcr-Abl, IgH-Bcl2, and LMO2-TCR translocations
are frequently found in nonleukemic individuals who do not
subsequently develop leukemias [45]. Based in part on the
detection of Bcr-Abl in peripheral blood of healthy people
for several months to years, an argument has been made that
Bcr-Abl translocations must occur frequently in HSCs of
people that never develop leukemia [46]. In light of the data
presented here, we suggest that the relative inability of
progenitor cells possessing Bcr-Abl translocations to compet-
Figure 9. The Poor Competition Model
In a wild-type, healthy progenitor cell pool, potentially oncogenic
mutations (represented as a red ‘‘X’’ in a cell) will often provide little or
no advantage in the short term, and may even be disadvantageous (top
images). In contrast, in a replication-impaired hematopoietic system
(bottom images), acquisition of some oncogenic mutations should
provide a selective advantage by partly or fully restoring cell cycle
progression, even when the same mutation might be disadvantageous
in a wild-type pool. The preferential expansion of the mutated
population increases the target size and thus the chances for additional
mutations and cancer. In this figure, the rectangle indicates the limited
niche size, implying competition for contacts and growth factors. The
thickness of curved arrows indicates proliferative ability.
DOI: 10.1371/journal.pbio.0030401.g009
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itively expand and to acquire additional mutations under
most contexts limits the development of leukemia.
Our result that HU promotes Bcr-Abl-dependent leuke-
mias may seem surprising, given that HU is used for
cytoreduction of CML cells in patients. However, in human
disease the leukemic cells are already established and
dominant, while our experiments are more relevant to the
context of leukemia initiation. Thus, our use of HU may be
less pertinent to the use of this drug to treat CML, but can be
viewed as a general means to suppress S phase progression in
the hematopoietic system, which is relevant to the effects of
clinically used drugs or other conditions that inhibit DNA
replication in progenitor populations. Indeed, a number of
contexts that have been presumed or demonstrated to reduce
dNTP production are associated with increased cancer rates,
including folate deficiency [14] and polymorphisms resulting
in decreased thymidylate synthase expression [47]. These
contexts of dNTP restriction are thought to promote cancer
in part by increasing mutation rates, and our results suggest
that poorly competitive stem cell pools also play an
important role. While links between Bcr-Ablþ CML or ALL
incidence and dietary variables or polymorphisms affecting
dNTP metabolism have not been sufficiently examined, based
on our demonstration that the inhibition of dNTP synthesis
by HU promotes Bcr-Abl-dependent leukemias, such studies
are warranted.
HU induces replication-associated double-stranded DNA
breaks in cultured cells [15,16], although whether HU induces
DNA damage or mutagenesis in vivo is still unresolved. Long-
term treatment of sickle cell anemia patients with HU does
not result in increased mutation rates or cancer formation
[48]. However, some studies have found an association
between cytoreductive HU treatment of myeloproliferative
disorders and the development of acute leukemias, including
a high proportion with 17p deletion [49,50]. Still, while
commonly used chemotherapeutic antimetabolites such as
HU and methotrexate do not appear to be substantially
leukemogenic when used as single agents [48,51], combina-
tions of antimetabolites with etoposide are associated with
higher incidences of treatment-related leukemias relative to
etoposide alone [17]. While clinical experiences are insuffi-
ciently controlled to conclude that antimetabolite therapies
contribute to secondary leukemias, our demonstration that a
chemotherapeutic agent that inhibits dNTP synthesis can
promote leukemia suggests that this issue needs to be further
addressed in the clinic. The inhibition of DNA replication by
antimetabolites may promote the competitive expansion of
progenitor cells acquiring etoposide-induced oncogenic
mutations, much as HU promotes the expansion of Bcr-Abl-
expressing progenitors. Thus, conditions that generally
impair DNA replication, such as drugs that inhibit dNTP
synthesis, may function as tumor promoters for oncogenically
initiated cells by creating a poorly competitive environment.
This view contrasts with the generally described function of
tumor promoters as enhancers of proliferation.
Finally, while numerous properties of E2F1 and E2F2,
including gene repression and the promotion of apoptosis
and DNA repair, have been suggested to underlie observed
increases in tumors in E2f1 and E2f2 mutant mice (reviewed
in [11,12]), we demonstrate that the promotion of Bcr-Abl-
dependent leukemias and the expansion of p53 mutant cells
by E2f1/E2f2 disruption result from non-cell autonomous
consequences of E2f loss. According to our model, E2f1/E2f2
mutations at least in part predispose mice to tumors, since
the E2f genes are disrupted in all cells in the mouse, thus
providing a poorly competitive progenitor population. In
contrast, loss-of-function mutations in E2f1 or E2f2 in an
individual cell would not be expected to provide an
advantage to the cell, and thus would not contribute to
tumorigenesis, thus perhaps explaining the paucity of such
mutations in human tumors. Poor competition should select
for oncogenic mutations only when the entire population of
competing cells are similarly debilitated.
In summary, we have demonstrated that impaired DNA
replication in hematopoietic progenitor pools contributes to
a powerful selection for mutations (such as Bcr-Abl trans-
location) that improve cell cycle progression, providing a
selective advantage over the poor competition offered by
replication-debilitated progenitors and thus promoting
leukemogenesis. As cancer development has attributes clearly
reminiscent of Darwinian evolution, it is logical that it should
become easier for a mutant cell clone to be the ‘‘fittest’’ as the
quality of the competition declines. Thus, as with the natural
selection of species, poor fitness selects for adaptive
mutations in stem cell pools.
Materials and Methods
Mice. The generation of the E2f1 and E2f2 mutant mice (back-
crossed seven times into BALB/c) has been previously described
[52,53]. BALB/c and p53/ mice were purchased from Jackson Labs
(Bar Harbor, Maine, United States). GFP transgenic mice were the
generous gift of Dr. Brian Schaefer, and were backcrossed with p53
mutation into the BALB/c background. The University of Colorado
Health Sciences Center Animal Care and Use Committee approved
all mouse experiments.
Retroviral constructs. The retroviral MSCV-iresGFP vectors
expressing either p190 or p210 Bcr-Abl were provided by Drs.
Zhonghan Dai and Warren Pear. MSCV-Bcl2-iresGFP was provided by
Dr. Scott Lowe. To construct similar retroviral vectors expressing
DNp53 and DDp53, the p53Arg175His cDNA fragment from plasmid
pCMV-NEO pC53–175 (provided by Dr. Bert Vogelstein) and DDp53
cDNA from pLXSNp53DD (provided by Dr. Xiao-Fan Wang) were
cloned into the MSCV-iresGFP vector.
Retroviral transduction and bone marrow transplantation. MSCV
viruses were prepared by transient transfection of Phoenix-E cells
together with pCL-Eco, and titered on fibroblasts using GFP as the
marker, so that similar multiplicities of infection for oncogene and
vector viruses were used. Donor DKO, E2f1þ2þ, or wild-type mice
were injected intraperitoneally with 100 mg/kg 5-fluorouracil (Sigma,
St. Louis, Missouri, United States) 3 d prior to BM harvest. Harvested
donor BM cells were enriched for c-Kitþ cells by MACS (Miltenyi
Biotec, Bad Gladbach, Germany) and then cultured overnight in
IMDM plus 15% defined fetal bovine serum (HyClone, South Logan,
Utah, United States) and 0.1% bovine serum antigen (Sigma), with the
cytokines 100 ng/ml human stem cell factor (gift from Dr. Chris
Hogan), 100 ng/ml human IL-11 (PeproTech, Rocky Hill, New Jersey,
United States),1.5 ng/ml mouse IL-3 (PeproTech), and 100 ng/ml hIL-6
(PeproTech). Cells were transduced with MSCV-containing super-
natants (;1/5 volume) supplemented with 6 lg/ml Polybrene (Sigma)
for 6 h. Cells were then transplanted intravenously into lethally (1,200
Rads for E2F experiments) or sublethally (600 Rads for HU experi-
ments) irradiated BALB/c mice. A subset of the transduced cells was
further cultured for 2 d, and the percentage of GFPþ cells was
determined by flow cytometry in order to determine the initial
infection efficiency. Ex vivo culturing of Bcr-Abl-transduced cells for
Figure 5 was performed under the same culture conditions.
Flow cytometry and cell cycle analysis. Single-cell suspensions were
washed in PBS containing 5% FBS (FBS-PBS). About 106 cells were
stained in 20 ll of antibody solution (1:100 dilution of each antibody)
for 30 min at room temperature. Cells were washed once with 1 ml of
FBS-PBS and resuspended in 400 ll of PBS for flow cytometric
analysis. The following PharMingen (San Diego, California, United
States) antibodies against mouse were used: phycoerythrin (PE)-
linked anti-B220, PE-anti-Ter119, PE-anti-GR-1, PE-anti-CD3, PE-
PLoS Biology | www.plosbiology.org December 2005 | Volume 3 | Issue 12 | e4012145
Poor Competition Promotes Tumorigenesis
anti-CD4, PE-anti-Flk2/Flt3, and PE-anti-CD43; and allophycocyanin
(APC)-linked anti-B220, APC-anti-Thy1.2, and APC-anti-CD117; and
biotin-linked anti-GR-1, biotin-anti-CD34, biotin-anti-IgM, and PE-
cyanine (PE-Cy7)-linked anti-biotin. APC-anti-Sca1 antibodies were
purchased from eBioscience (San Diego, California, United States).
Fluorescence was detected with a Cytomics FC 500 (Beckman Coulter,
Allendale, New Jersey, United States) cytometer. For BrdU incorpo-
ration analyses, mice were injected intraperitoneally with BrdU (1 mg
per 25 g of body weight; Roche, Indianapolis, Indiana). After 2 h,
pooled spleen and BM cells were purified using a MoFlo (Cytomation,
Fort Collins, Colorado, United States) cell sorter for GFPþ or GFP
subsets of progenitors: B220þplus GR-1þ (B-cell and myeloid lineages)
for Figure 3 or Lin for Figure 6. Immunofluorescence, flow
cytometric analyses, and calculations of the length of S phase were
performed as described previously [7,20].
Pathology. Mice were monitored for disease development, as
judged by increasing percentages of GFPþ cells with blast morphology
in peripheral blood of transplanted animals, as well as symptoms,
such as abnormal gait and labored breathing. Moribund animals were
sacrificed and examined for tumors. Touch preps and tissue sections
were obtained from spleen and liver.
Supporting Information
Figure S1. The Loss of E2f1 and E2f2 Promotes the Competitive
Repopulation of the B Cell Lineage by Bcr-Abl-Expressing Progenitors
C-kitþ cells from either E2f1þ2þ or DKO donor mice were transduced
at low- and high-efficiency and transplanted as in Figures 2 and 4
(same experiments). The graph shows the changes in the percentages
of GFPþ cells in the peripheral B220þ lineage of Bcr-Abl transduced
E2f1þ2þE2F1þ recipients (left), Bcr-Abl transduced DKO recipients
(middle) and Bcr-Abl transduced DKO recipients supplemented with
untransduced E2f1þ2þ competitor progenitors (right). Each curve
follows the individual mouse used in experiments with low (upper)
and high (lower) transduction efficiency. Curves end if the mouse
develops leukemia and is sacrificed prior to the next tail blood
analysis. Surviving mice from the Bcr-Abl!E2f1þ2þ and Bcr-Abl!DKO
þ E2f1þ2þ competitors groups were bled at 180 and 240 d post-BMT
(for low- and high-transduction experiments, respectively), and no
GFPþ cells were detected above background in any recipient
(unpublished data).
Found at DOI: 10.1371/journal.pbio.0030401.sg001 (54 KB PPT).
Figure S2. Inhibition of Apoptosis by Bcl2 Overexpression Does Not
Provide a Competitive Advantage to DKO Relative to E2f1þ2þ
Progenitors
E2f1þ2þ or DKO BM cells were transduced with MSCV viruses
expressing Bcl2 (with iresGFP), and then transplanted into lethally
irradiated BALB/c mice. The mice were sacrificed at 3 wk post-
transplant, and flow cytometric analysis of GFP and GR-1 expression
in BM was performed. Initial infection efficiencies for both genotypes
were similar. MSCV-expressed Bcl2 is functional, given that it
conferred increased survival to BM progenitor cultures from
E2f1þ2þ and DKO mice (unpublished data).
Found at DOI: 10.1371/journal.pbio.0030401.sg002 (54 KB PPT).
Figure S3. HU Treatment Increases p190 Bcr-Abl-Mediated Leuke-
mogenesis in the Rag2/ Background
(A) C-Kitþ cells from Rag2/ BM (BALB/c congenic) were transduced
with MSCV-p190 Bcr-Abl, and transplanted into lethally irradiated
BALB/c recipients as in Figure 2. At 2 wk post-BMT, half of each
group was switched to water containing HU. The average percent
GFPþ in peripheral blood cells was 10%, and mice with similar
percentages were segregated into the HU treated and untreated
groups. Kaplan-Meier curves for transplanted mice are shown. Mice
were sacrificed when moribund; all with splenomegaly and massive
increases in GFPþ cells in the spleen and peripheral blood.
(B) Representative flow cytometric plots are shown for recipients of
Bcr-Abl-transduced Rag2/ BM. Peripheral blood cells of the trans-
planted mice were analyzed for the expression of CD3 and IgM 2 wk
post-BMT (before HU treatment). Cells expressing these markers (T
and B cells) were almost undetectable in transplanted animals (left).
Spleen cells from morbid Bcr-Abl/Rag2/ (with and without HU) mice
were analyzed for the expression of GFP, B220, Ter119, GR-1, and
Thy1.2. Leukemias arising in untreated and HU-treated mice did not
express B220 and Thy1.2 (unpublished data), but displayed many GR-
1þ and Ter119þ cells (right; gated on GFPþ blast population). A similar
blast population expressing both myeloid (GR-1þ) and erythroid
(Ter119þ) markers was present in the one morbid non-HU treated
recipient (unpublished data).
Found at DOI: 10.1371/journal.pbio.0030401.sg003 (114 KB PPT).
Figure S4. Recipients of Bcr-Abl-Transduced Progenitors That Devel-
oped Leukemias With or Without HU Treatment Exhibited Spleno-
megaly and High Numbers of Leukocytic Blasts in Peripheral Blood
Recipients of vector or p190 Bcr-Abl transduced progenitors were
treated or not with HU as in Figure 7 and sacrificed when morbid.
Peripheral blood from the tail vein was drawn before sacrifice and
analyzed for a complete blood count using a Cell-Dyn 1700 System.
HU treatment of vector recipients did result in modest but significant
(p , 0.05) leukopenia. For Bcr-Abl recipients with or without HU
treatment, high peripheral leukocyte counts were evident, most of
which were blasts (also confirmed microscopically), but the difference
between HU-treated and untreated was not statistically significant.
Following sacrifice, spleens were weighed. The increased spleen
weight in HU-treated relative to untreated recipients of Bcr-Abl
transduced progenitors is significant (p, 0.05). The average weight of
a spleen from a healthy mouse is about 0.1 g.
Found at DOI: 10.1371/journal.pbio.0030401.sg004 (40 KB PPT).
Figure S5. Leukemias That Developed in Untreated and HU-Treated
Animals Were Transferable
BM cells (53103, 53104, and 53105) from morbid leukemic HU and
non-HU treated Bcr-Abl BMT recipients were transplanted into
BALB/c recipients. The fraction of transplanted mice that developed
secondary leukemias is shown, and the time post-transplant that mice
became morbid indicated in parentheses. Similar results were
obtained with spleen cells from a different set of leukemic donors.
Found at DOI: 10.1371/journal.pbio.0030401.sg005 (36 KB PPT).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) accession num-
bers of the genes discussed in this paper are Bcr-Abl (X06418), E2f1
(L21973), E2f2 (AK087452), and p53 (P04637).
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